Overall, this work elucidates a novel CRLF1-SIN1/AKT-pyroptosis axis that drives chemoresistance in ovarian cancer, firmly establishing CRLF1 as a promising therapeutic target warranting further exploration. The gene discussed is AKT1; the disease is ovarian carcinoma.